# Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Diet and Exercise Alone（UNIGUIDE-1）

Study · id `cardio:ct-nct07659574` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07659574](<https://clinicaltrials.gov/study/NCT07659574>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07659574

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 360 participants.

## Technical summary

Registry record NCT07659574. Randomized; triple masking; primary purpose treatment. Start 2026-09-07 (actual); primary completion 2027-09-24 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 360 participants (planned count; ClinicalTrials.gov record NCT07659574, source copy `cardio:ctgov-nct07659574-2026-09-15`, retrieved 2026-10-26)
- Started: 2026-09-07 (actual) (ClinicalTrials.gov record NCT07659574, source copy `cardio:ctgov-nct07659574-2026-09-15`, retrieved 2026-10-26)
- Primary completion: 2027-09-24 (anticipated) (ClinicalTrials.gov record NCT07659574, source copy `cardio:ctgov-nct07659574-2026-09-15`, retrieved 2026-10-26)
- Completion: 2027-10-22 (anticipated) (ClinicalTrials.gov record NCT07659574, source copy `cardio:ctgov-nct07659574-2026-09-15`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07659574, source copy `cardio:ctgov-nct07659574-2026-09-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07659574-2026-09-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Diet and Exercise Alone（UNIGUIDE-1）
- Acronym: UNIGUIDE-1
- Condition: Type 2 Diabetes
- Intervention (Drug): UBT251 Injection 2.0 mg
- Intervention (Drug): UBT251 Injection 4.0 mg
- Intervention (Drug): UBT251 Injection 6.0 mg
- Intervention (Drug): UBT251 Injection Placebo 2.0 mg
- Intervention (Drug): UBT251 Injection Placebo 4.0 mg
- Intervention (Drug): UBT251 Injection Placebo 6.0 mg
- Lead sponsor: The United Bio-Technology (Hengqin) Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: The United Bio-Technology (Hengqin) Co., Ltd. (`cardio:org-the-united-bio-technology-hengqin-co-ltd`)

## Provenance

Content hash: 6b8c141c27d72f3eda308395b802c051350d4fc2dba386fc97d771b97deae12d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
